focus -WSS

focus

author：leisure time 2025-09-28 23:24:26 - browse：7

Senator Ron Wyden (D-OR) speaks with reporters in the Senate subway at the U.S. Capitol — Sen. Ron Wyden (D-Ore.) Drew Angerer/Getty Images

Senate Finance Committee members from both parties took aim Wednesday at insurance brokers that sell plans for large Medicare Advantage insurers.

Older adults at times have more than 100 plan options, and brokers help them choose the right one. But brokers can be incentivized by large insurance companies to aggressively sell plans that are a poor fit for the Medicare beneficiaries they’re supposed to help. Brokers also sometimes collect private information that they sell to multiple insurance companies. Those brokers tend to have a national scope, just like the large insurers they represent, compared to the independent, local brokers.

“They are big private marketing companies in the middle between seniors and their coverage,” Chairman Ron Wyden (D-Ore.) said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： A new study asks: Are we harming blood donors by taking blood?

leisure time

WSS

Australia's humpback populations rebound raising hopes of marine scientists

Meta looks to target Twitter with a rival app called Threads

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Pfizer's Covid pill remains 89% effective in final analysis, company says

Chemotherapy drug shortage eases slightly but still widespread

A virus, fished out of a lake, may have saved a man’s life

explore

focus

hotspot

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

A new study asks: Are we harming blood donors by taking blood?

BioMarin wins approval for gene therapy to treat hemophilia A

4th of July breaks record for highest global temperature ever measured

Virginia high school admissions case could be legal follow

Was Amgen transparent enough on FDA's concern on cancer drug?

Wildfire smoke exposes gaps in outdoor worker protections

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

23andMe had bad news about my health. I wish a person had delivered it

Physician executives need more than on

focus

Bristol 'take

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Doctor appointment wait times are getting worse

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

Make 'food is medicine' a key part of White House nutrition meeting

Australia's humpback populations rebound raising hopes of marine scientists

leisure time

leisure time

focus

hotspot